ChiCTR2000035004 版本V1.0 版本创建时间2020/07/27 23:45:02 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000035004 

最近更新日期:

Date of Last Refreshed on:

2020-07-27 23:44:56 

注册时间:

Date of Registration:

1990-01-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

审核中(一)王守丽医师:该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传批件。 胆汁反流性胃炎和胃癌患者胃液代谢组学研究

Public title:

Research of gastric juice metabolomics in patients with bile reflux gastritis and gastric cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胆汁反流性胃炎和胃癌患者胃液代谢组学研究

Scientific title:

Research of gastric juice metabolomics in patients with bile reflux gastritis and gastric cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王守丽 

研究负责人:

赵爱华 

Applicant:

Shouli Wang 

Study leader:

Aihua Zhao 

申请注册联系人电话:

Applicant telephone:

15021092907

研究负责人电话:

Study leader's telephone:

021-24056374

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

balihewangshouli@163.com

研究负责人电子邮件:

Study leader's E-mail:

zhah@sjtu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区宜山路600号科研楼17楼办公室4

研究负责人通讯地址:

上海市徐汇区宜山路600号科研楼17楼办公室3

Applicant address:

Office Room 4, 17th Floor, Scientific Research Building, 600 Yishan Road, Xuhui District, Shanghai

Study leader's address:

Office Room 3, 17th Floor, Scientific Research Building, 600 Yishan Road, Xuhui District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第六人民医院

Applicant's institution:

Shanghai Sixth People's Hospital

研究负责人所在单位:

上海市第六人民医院

Affiliation of the Leader:

Shanghai Sixth People's Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第六人民医院

Primary sponsor:

Shanghai Sixth People's Hospital

研究实施负责(组长)单位地址:

上海市徐汇区宜山路600号

Primary sponsor's address:

600 Yishan Road, Xuhui District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院

具体地址:

徐汇区宜山路600号

Institution
hospital:

Shanghai Sixth People's Hospital

Address:

600 Yishan Road, Xuhui District

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China

Target disease:

bile reflux gastritis and gastric cancer

Target disease code:

研究类型:

基础科学研究

Study type:

Basic Science

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

胃癌是原发于胃上皮的恶性肿瘤,发病率和死亡率高居不下,但是其病因仍不明确。近年来大量临床研究表明胆汁反流是胃癌发生发展的危险因素之一,且大量基础研究显示胆汁酸对于胃癌细胞的增殖具有促进作用,但是关于胆汁酸如何促进胃癌的相关机制研究却很少。胆汁酸反流进入胃腔内,改变了胃内原有的生态环境,打破了原有的微生态平衡。因此本文旨在探究胆汁酸在胃癌进展过程中的作用,为胃癌的发病机制研究、临床预防和治疗提供参考。  

Objectives of Study:

Gastric cancer is a malignant tumor that originates from the epithelium of the stomach, with a high morbidity and mortality rate, but its etiology is still unclear. In recent years, a large number of clinical studies have shown that bile reflux is one of the risk factors for the occurrence and development of gastric cancer, and a large number of basic studies have shown that bile acid can promote the proliferation of gastric cancer cells, but there are few studies on how bile acids promote gastric cancer. The reflux of bile acids into the stomach cavity changes the original ecological environment in the stomach and breaks the original microecological balance. Therefore, this research aims to explore the role of bile acids in the progression of gastric cancer, and to provide references for the pathogenesis, clinical prevention and treatment of gastric cancer.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 中国人
② 胃镜下胃底粘液湖有胆汁样浑浊或组织学或细胞学诊断为胃腺癌者;
③ 不合并其他急、慢性疾病;
④ 年龄18-75岁;
⑤ 签署知情同意书。

Inclusion criteria

① Chinese.
② Those who have bile-like turbidity in the mucus lake of the fundus of the stomach under gastroscope or diagnosed as gastric adenocarcinoma by histology or cytology.
③ No other acute or chronic diseases.
④ 18-75 years old.
⑤ Sign informed consent.

排除标准:

① 有胃食管反流病;
② 有消化道溃疡等急慢性消化道疾病;
③ 有其他癌症;
④ 患病期间,或研究前4周内使用抗生素者;
⑤ 常规服用处方的中西药物者;
⑥ 妊娠期或哺乳期女性。
⑦ 经主治医师判断不能或不适合进行胃镜检查者;
⑧ 本研究开始前4周正在参加或已经参加其他临床研究者。

Exclusion criteria:

① Those who have gastroesophageal reflux disease.
② Those who hvae acute and chronic digestive tract diseases such as digestrive ulcer.
③ Those who have other cancers.
④ Those who used antibiotics during the illness or within four weeks before the study.
⑤ Those who routinely take prescription Chinese and Western medicines.
⑥ Women who are pregnant or breastfeeding.
⑦ Those who have been judged by the attending physician to be unable or unsuitable for gastroscopy.
⑧ Those who are participating in or have participated in other clinical research four weeks before the start of this study.

研究实施时间:

Study execute time:

From 2020-07-30 00:00:00 To 2020-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-08-10 00:00:00 To 2020-11-30 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

100

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

胆汁反流性胃炎组

样本量:

100

Group:

bile reflux gastritis

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

胃癌组

样本量:

100

Group:

gastric cancer

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市第六人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Sixth People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

胃液胆汁酸代谢谱

指标类型:

主要指标

Outcome:

metabolomic profile of bile acid in gastric juice

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

废弃的胃液

组织:

Sample Name:

discarded gastric juice

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及随机方法。

Randomization Procedure (please state who generates the random number sequence and by what method):

No random methods are involved.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开日期:2021年12月份;公开方式:ResMan,网址:www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Date of publication: December 2021; Way of publication: ResMan, Website: www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据包括原始记录和病例相关信息等,采用ResMan进行管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data including original records and case related information were managed by ResMan.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-07-27 23:44:56